MRK vs NVS stock comparison
Merck & Co. vs. Novartis · data as of November 13, 2026
Merck & Co. (MRK) has a market value of about $364.3B, Novartis (NVS) about $306.3B. Over their latest twelve months Merck & Co. had revenue of $67.4B and Novartis $57.4B.
On our five checks Merck & Co. scores higher: 2.8 out of 5 (average) against 2.0 (weak).
By area, the stronger company is Merck & Co. on future growth; Merck & Co. on track record; Novartis on financial health; Merck & Co. on shareholder returns.
Novartis is cheaper on earnings (P/E 30.7 vs. 150.8), while Merck & Co. grew revenue faster over five years (9.4% vs. 2.3% a year).
Merck & Co. leads on 9 of the compared lines and Novartis on 15.
Side by side
| MRK | NVS | |
|---|---|---|
| Size and price | ||
| Market cap | $364.3B | $306.3B |
| Share price | $147.76 | $160.50 |
| Score | ||
| Overall score (of 5) | 2.8 | 2.0 |
| Value | 0 | 0 |
| Future growth | 2 | 0 |
| Track record | 5 | 4 |
| Financial health | 2 | 3 |
| Shareholder returns | 5 | 3 |
| Valuation | ||
| P/E (TTM) | 150.8 | 30.7 |
| Forward P/E | 17.6 | 17.0 |
| Price / free cash flow | 24.7 | 21.9 |
| Price / sales | 5.4 | 5.3 |
| EV / EBITDA | 32.5 | 14.4 |
| PEG | 7.10 | 2.02 |
| DCF value vs. price | −31% | −9% |
| Business | ||
| Revenue | $67.4B | $57.4B |
| Net income | $2.5B | $10.0B |
| Free cash flow | $14.7B | $14.0B |
| Net margin | 3.6% | 17.5% |
| Gross margin (5-yr avg.) | 73.4% | 76.4% |
| ROIC (5-yr avg.) | 16.3% | 14.1% |
| Growth | ||
| Revenue growth (1 yr) | 1.3% | 8.4% |
| Revenue growth (5 yrs, per year) | 9.4% | 2.3% |
| EPS growth (5 yrs, per year) | 21.2% | 15.2% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$44.1B | -$39.3B |
| Dividend yield | 2.30% | 2.95% |
| Shareholder yield | 3.7% | 6.0% |
| Analysts | ||
| Upside to average target | +9% | −2% |
| Consensus rating | Buy | Hold |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: MRK TTM to September 30, 2026, NVS TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Merck & Co. or Novartis?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Merck & Co. scores 2.8 out of 5 and Novartis 2.0; the table shows where each one is stronger.
Is Merck & Co. cheaper than Novartis?
On trailing earnings, Novartis trades at a P/E of 30.7 and Merck & Co. at 150.8, so Novartis is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Merck & Co. or Novartis?
Over five years Merck & Co. grew revenue about 9.4% a year and Novartis about 2.3% a year.
Which pays a higher dividend?
Merck & Co. yields 2.30% and Novartis 2.95%.
Full Merck & Co. analysis → Full Novartis analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.